Zogenix, Inc. (NASDAQ:ZGNX) will be discussing 3Q20 financial results with the investment community.on 9th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.zogenix.com
Earnings Expectation
Zogenix, Inc. is set to announce third quarter earning results on Monday 9th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ZGNX to report 3Q20 loss of $ 0.98 per share. For the full year, analysts anticipate top line of $ 13.36 million, while looking forward to loss of $ 3.54 per share bottom line.
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc.
